1
|
Schilling J, Hielscher C, Hanusch C, Kurbacher C, Busch S, Karthaus M. Abstract P1-11-10: Efficacy of NEPA as antiemetic prophylaxis in breast cancer patients receiving highly or moderately emetogenic chemotherapy – Interim results of a German prospective, non-interventional study. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p1-11-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
The oral fixed dose combination of netupitant and palonosetron NEPA has been approved for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in cancer patients receiving cisplatin-based highly emetogenic (HEC) or moderately emetogenic chemotherapy (MEC). The primary objective of the prospective, non-interventional study (NIS) AkyPRO is the evaluation of quality of life in adults receiving MEC or HEC and NEPA for CINV prevention. Secondary endpoints are efficacy and safety of NEPA. Here we present an interim analysis of NEPA efficacy in the subgroup of breast cancer patients, who represent the largest subgroup (66%) of enrolled patients. Since September 2015, 2427 patients have been enrolled, of whom 986 are breast cancer patients.
Methods
The NIS has been designed to evaluate NEPA in 2,500 cancer patients receiving single day or two day MEC or HEC. QoL is recorded by FLIE questionnaires. Efficacy (complete response (CR, no vomiting, no rescue medication)), additional medication, and adverse events are recorded in patient diaries over three consecutive chemotherapy cycles. Additionally, physicians report their efficacy assessments of NEPA online, using an eCRF.
Results
At the cut-off date November 11, 2017, 2427 patients had been enrolled in the study. For the interim analysis 986 breast cancer patients were evaluated who had been fully documented in the eCRF at the cut-off date.
95% had an ECOG performance status of 0 or 1. 51% received adjuvant, 44% neoadjuvant, and 5% palliative chemotherapy. 80% of patients received HEC, mostly (79%) anthracycline/cyclophosphamide (AC) combinations. Of the women receiving MEC, the majority were treated with carboplatin-based regimens (9%). 7% of patients received other MEC regimens.
81.4-82.8 % of patients reported CR in cycles 1-3 and more than 93% of patients reported no emesis during the 3 treatment cycles covered in the patient diaries. No significant nausea was reported by 62.7-64.2% of patients.
Physicians rated the efficacy of the antiemetic prophylaxis with NEPA using the 4 categories very good, good, satisfactory, and poor. In cycles 1 and 2, more than 89% of physicians rated the efficacy of NEPA very good or good. In cycle 3, 90.6% rated it very good or good. In addition to reporting CR, nausea and emesis episodes in their patient diaries, patients used the same 4 categories to assess the efficacy of NEPA at the end of each treatment cycle. Efficacy assessments of physicians and patients were very similar, with 87% of patients choosing very good or good in cycle 1 compared to 89% of physicians.
NEPA was well tolerated. Low-grade constipation (14.9%) and insomnia (8.3%) were the most frequent treatment-related adverse event.
Conclusion
In this real life study, NEPA was effective in the prevention of CINV in the subgroup of breast cancer patients receiving HEC or MEC. The efficacy assessments by patients and physicians were comparable, with approximately 90% good or very good efficacy for 3 consecutive cycles. More than 93% of patients reported no emesis and more than 81% reported CR during the 5 days post-chemotherapy during all 3 cycles. The study is ongoing.
Citation Format: Schilling J, Hielscher C, Hanusch C, Kurbacher C, Busch S, Karthaus M. Efficacy of NEPA as antiemetic prophylaxis in breast cancer patients receiving highly or moderately emetogenic chemotherapy – Interim results of a German prospective, non-interventional study [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-11-10.
Collapse
Affiliation(s)
- J Schilling
- Gynaeko-onkologische Gemeinschaftspraxis, Berlin, Germany; g.SUND Gynaekologie Kompetenzzentrum, Stralsund, Germany; Rotkreuzklinikum Muenchen Frauenklinik, Munich, Germany; Gynaekologische Zentrum Bonn, Bonn, Germany; Praxis für Frauenheilkunde, Muehlhausen, Germany; Staedtisches Klinikum Muenchen Neuperlach, Munich, Germany
| | - C Hielscher
- Gynaeko-onkologische Gemeinschaftspraxis, Berlin, Germany; g.SUND Gynaekologie Kompetenzzentrum, Stralsund, Germany; Rotkreuzklinikum Muenchen Frauenklinik, Munich, Germany; Gynaekologische Zentrum Bonn, Bonn, Germany; Praxis für Frauenheilkunde, Muehlhausen, Germany; Staedtisches Klinikum Muenchen Neuperlach, Munich, Germany
| | - C Hanusch
- Gynaeko-onkologische Gemeinschaftspraxis, Berlin, Germany; g.SUND Gynaekologie Kompetenzzentrum, Stralsund, Germany; Rotkreuzklinikum Muenchen Frauenklinik, Munich, Germany; Gynaekologische Zentrum Bonn, Bonn, Germany; Praxis für Frauenheilkunde, Muehlhausen, Germany; Staedtisches Klinikum Muenchen Neuperlach, Munich, Germany
| | - C Kurbacher
- Gynaeko-onkologische Gemeinschaftspraxis, Berlin, Germany; g.SUND Gynaekologie Kompetenzzentrum, Stralsund, Germany; Rotkreuzklinikum Muenchen Frauenklinik, Munich, Germany; Gynaekologische Zentrum Bonn, Bonn, Germany; Praxis für Frauenheilkunde, Muehlhausen, Germany; Staedtisches Klinikum Muenchen Neuperlach, Munich, Germany
| | - S Busch
- Gynaeko-onkologische Gemeinschaftspraxis, Berlin, Germany; g.SUND Gynaekologie Kompetenzzentrum, Stralsund, Germany; Rotkreuzklinikum Muenchen Frauenklinik, Munich, Germany; Gynaekologische Zentrum Bonn, Bonn, Germany; Praxis für Frauenheilkunde, Muehlhausen, Germany; Staedtisches Klinikum Muenchen Neuperlach, Munich, Germany
| | - M Karthaus
- Gynaeko-onkologische Gemeinschaftspraxis, Berlin, Germany; g.SUND Gynaekologie Kompetenzzentrum, Stralsund, Germany; Rotkreuzklinikum Muenchen Frauenklinik, Munich, Germany; Gynaekologische Zentrum Bonn, Bonn, Germany; Praxis für Frauenheilkunde, Muehlhausen, Germany; Staedtisches Klinikum Muenchen Neuperlach, Munich, Germany
| |
Collapse
|
2
|
Fasching PA, Eggemann H, Krocker J, Häberle L, Volz B, Kleine-Tebbe A, Blohmer JU, Kittel K, Hufnagel M, Janni W, Emons G, Simon E, Köhler U, Thomssen C, Kohls A, Beckmann MW, Hielscher C, Krabisch P, Zeiser T, Brodkorb T, Baier F, Nabieva N, Kellner S, Untch M, Stadie S, Budner M, Breitbach GP, Keller M, Stickeler E, Kühn T, Tolkmitt M, Belau AK, Schmidt M, Ulm K, Kümmel S. Abstract P1-13-01: Final results of the ASG1-3 study, a randomized phase III study comparing a standard dose chemotherapy with epirubicin/cyclophosphamide and paclitaxel with a dose dense regimen with epirubicin and paclitaxel. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p1-13-01] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Dose dense chemotherapy (DDT) has shown improvements of disease-free survival (DFS) and overall survival for primary breast cancer patients with a high risk of relapse. There are much less data about the effect of DDT in patients with intermediate risk of recurrence (1-3 positive axillary lymph nodes). Aim of this prospectively randomized trial was to investigate the superiority of a DDT schedule over a standard chemotherapy (ST) in primary breast cancer patients with 1-3 positive axillary lymph nodes.
Methods
The ASG1-3 study is a prospectively randomized, open label phase III study of the Adjuvant Study Group of the NOGGO association. Patients were eligible for the trial, if they had a primary invasive breast cancer (pT1-3) with 1-3 positive axillary lymph nodes and no evidence of distant metastases. Patients were randomized to an adjuvant therapy with either 4 cycles epirubicin (90mg/m2 body surface area, BSA) and cyclophosphamide (600mg/m2 BSA) q3w, followed by 4 cycles of paclitaxel (175mg/m2 BSA) referred to as ST or to a therapy with 4 cycles of epicubicin (120 mg/m2 BSA) q2w and primary G-CSF support followed by 4 cycles of paclitaxel (175mg/m2 BSA) q2w and primary G-CSF support referred to as DDT. Trastuzumab was not given in this study. The study was designed to show an increase of 70% DFS (ST) to 80% DFS (DDT) 5 years after randomization. Comparisons were conducted using Kaplan Meier estimates, log rank tests and Cox regression analyses. In an exploratory way, subgroup analyses were performed for HER2, hormone receptor status and grading using Cox regression models with interaction terms.
Results
A total of 936 patients were eligible for survival analysis, of which 465 were randomized to ST and 471 to DDT from 2001 to 2004. Patient characteristics were mainly well balanced, with patients being 52.5/52.1 years old, 71.9/78.1% being hormone receptor positive, 24.4/24.6% being HER2 positive and 38.6/38.8% having a tumor grade of 3 in the ST arm and DDT arm respectively. 53 events occurred after ST and 46 after DDT. Adjusted hazard ratio (HR) was 0.87 (95%CI: 0.57-1.35; p=0.54). 5 year DFS rates were 85% (ST) vs. 87% (DDT). Hematological toxicities were the most common grade 3 or 4 adverse events. Grade 3/4 neutropenia occurred in 57.2 vs. 28.0%, grade 3/4 anemia in 15.3% vs. 17.1% and grade 3 /4 pain symptoms were seen in 13.2 vs. 12.4% of the patients in the ST arm vs. DDT arm respectively. Other grade 3/4 toxicities were less frequent than 10%. Subgroup analysis showed a significant interaction (p<0.001) between HER2 status and randomization arm with regard to DFS. In HER2 negative patients the HR was 1.53 (95%CI: 0.91-2.59), whereas in HER2 positive patients the HR was 0.22 (95%CI: 0.09-0.55). Patients with HER2 positive disease and DDT had a similar prognosis like HER2 negative patients.
Conclusion
In the overall population a statistically significant improvement of DFS could not be shown for the DDT arm. In patients with HER2 positive breast cancer DDT chemotherapy improved the disease-free survival to a prognosis which was similar to patients with HER2 negative disease.
Citation Format: Fasching PA, Eggemann H, Krocker J, Häberle L, Volz B, Kleine-Tebbe A, Blohmer J-U, Kittel K, Hufnagel M, Janni W, Emons G, Simon E, Köhler U, Thomssen C, Kohls A, Beckmann MW, Hielscher C, Krabisch P, Zeiser T, Brodkorb T, Baier F, Nabieva N, Kellner S, Untch M, Stadie S, Budner M, Breitbach G-P, Keller M, Stickeler E, Kühn T, Tolkmitt M, Belau AK, Schmidt M, Ulm K, Kümmel S. Final results of the ASG1-3 study, a randomized phase III study comparing a standard dose chemotherapy with epirubicin/cyclophosphamide and paclitaxel with a dose dense regimen with epirubicin and paclitaxel [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-13-01.
Collapse
Affiliation(s)
- PA Fasching
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - H Eggemann
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - J Krocker
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - L Häberle
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - B Volz
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - A Kleine-Tebbe
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - J-U Blohmer
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - K Kittel
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - M Hufnagel
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - W Janni
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - G Emons
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - E Simon
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - U Köhler
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - C Thomssen
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - A Kohls
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - MW Beckmann
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - C Hielscher
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - P Krabisch
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - T Zeiser
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - T Brodkorb
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - F Baier
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - N Nabieva
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - S Kellner
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - M Untch
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - S Stadie
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - M Budner
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - G-P Breitbach
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - M Keller
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - E Stickeler
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - T Kühn
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - M Tolkmitt
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - AK Belau
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - M Schmidt
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - K Ulm
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| | - S Kümmel
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; University Hospital Magedeburg, Magdeburg, Germany; Breast Cancer Center, Sana Klinkum Lichtenberg, Berlin, Germany; Biostatistics and Data Management Unit; University Hospital Erlangen, Erlangen, Germany; DRK-Kliniken Berlin Köpenick, Berlin, Germany; Charité University Hospital Campus Charité-Mitte, Berlin, Germany; Praxisklinik Krebsheilkunde für Frauen – Brustzentrum, Berlin, Germany; Ulm University Hospital, Ulm, Germany; University Hospital Göttingen, Göttingen, Germany; Torgau Hospital "Johann Kentmann" gGmbH, Torgau, Germany; Hospital St. Georg, Leipzig, Germany; Martin-Luther-University Halle-Wittenberg, Halle, Germany; Evang. Hospital Ludwigsfelde -Teltow gGmbH, Ludwigsfelde-Teltow, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Klinikum Chemnitz gGmbH, Chemnitz, Germany; Paracelsus Hospital, Henstedt-Ulzburg, Germany; Helios Clinics Berlin Buch, Berlin, Germany; Medical Centre, Pa
| |
Collapse
|
3
|
Müller V, Huober J, Volz B, Overkamp F, Kolberg HC, Hadji P, Haeberle L, Ettl J, Hartkopf AD, Lux MP, Lüftner DI, Wallwiener M, Taran FA, Beckmann MW, Belleville E, Wimberger P, Hielscher C, Geberth M, Lermann J, Abenhardt A, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Janni W, Fehm TN, Brucker SY, Wallwiener D, Schneeweiss A, Fasching PA, Tesch H. Abstract OT1-11-02: PRAEGNANT - Real world evidence, translational research, big and smart data: A prospective academic translational research network for the optimization of the oncological health care quality in the adjuvant and advanced/ metastatic setting (NCT02338167). Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-ot1-11-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
During the last decades the treatment of advanced breast cancer (ABC) patients has improved due to a variety of new treatment strategies. Nevertheless, many ABC patients are faced with limited prognosis, and their treatment remains a challenge. New targeted therapies complement the well-established treatment options for ABC (CDK4/6 inhibition, anti-endocrine, chemotherapy, antibody based and bone related therapies), leading to improved treatment regimens tailored to the needs of special patient sub-populations.
SPECIFIC AIMS/TRIAL DESIGN
The PRAEGNANT network study is conducted as an academic, prospective registry and diagnostic translational study, accompanied by biomaterial collection. The pilot phase in more than 60 centers aims at including 3500 ABC patients. The primary objective is to discover biomarkers, which predict progression free survival (PFS). Secondary objectives include overall survival (OS), breast cancer specific survival, objective response rate, patient reported outcomes (PRO), description of therapies used in the metastatic setting, therapy adherence, health economics for patients with ABC, incidence of (serious) adverse events and big data/ machine learning algorithms. The exploratory objectives comprise correlations of gene alterations and their influence on OS, PFS, side effects and PRO. Exploratory biomarkers are assessed at baseline and at every change of therapy. These biomarkers include gene expression profiling of the primary tumor and corresponding metastasis, somatic mutations (measured in the tumor and in circulating tumor DNA), germline genetic variations, epigenetic changes and miRNA variations. Furthermore, plasma and serum markers are assessed. If actionable molecular alterations are detected patients are informed and recruited into suitable studies if available.
ELIGIBILITY CRITERIA:
Any adult patient (>18 years) with the diagnosis of ABC and who is willing and able to sign the informed consent can be enrolled.
STATISTICAL METHODS/TARGET ACCRUAL:
The PRAEGNANT study as a prospective real world registry and diagnostic translational study aims to identify biomarkers in ABC patients, which may predict PFS. Target accrual for the pilot phase is 3500 patients. Each patient will be documented for up to 36 months with an estimated median PFS for all patients of 11 months across all treatment lines.
Citation Format: Müller V, Huober J, Volz B, Overkamp F, Kolberg H-C, Hadji P, Haeberle L, Ettl J, Hartkopf AD, Lux MP, Lüftner DI, Wallwiener M, Taran F-A, Beckmann MW, Belleville E, Wimberger P, Hielscher C, Geberth M, Lermann J, Abenhardt A, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Janni W, Fehm TN, Brucker SY, Wallwiener D, Schneeweiss A, Fasching PA, Tesch H. PRAEGNANT - Real world evidence, translational research, big and smart data: A prospective academic translational research network for the optimization of the oncological health care quality in the adjuvant and advanced/ metastatic setting (NCT02338167) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr OT1-11-02.
Collapse
Affiliation(s)
- V Müller
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - J Huober
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - B Volz
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - F Overkamp
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - H-C Kolberg
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - P Hadji
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - L Haeberle
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - J Ettl
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - AD Hartkopf
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - MP Lux
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - DI Lüftner
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - M Wallwiener
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - F-A Taran
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - MW Beckmann
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - E Belleville
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - P Wimberger
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - C Hielscher
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - M Geberth
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - J Lermann
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - A Abenhardt
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - C Kurbacher
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - R Wuerstlein
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - C Thomssen
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - M Untch
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - W Janni
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - TN Fehm
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - SY Brucker
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - D Wallwiener
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - A Schneeweiss
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - PA Fasching
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - H Tesch
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| |
Collapse
|
4
|
Lux MP, Hartkopf AD, Huober J, Volz B, Taran FA, Overkamp F, Hadji P, Tesch H, Haeberle L, Ettl J, Lueftner DI, Wallwiener M, Müller V, Beckmann MW, Belleville E, Wimberger P, Hielscher C, Geberth M, Lermann J, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Fasching PA, Janni W, Fehm TN, Wallwiener D, Brucker SY, Schneeweiss A, Kolberg HC. Abstract P6-17-37: Therapy landscape of patients with metastatic, HER2 positive breast cancer - Data from the real world breast cancer registry PRAEGNANT (NCT02338167). Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-17-37] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose:
This analysis describes comprehensive real-world data concerning the use of anti-HER2 therapies in HER2 positive metastatic breast cancer (MBC). Specifically, it describes the therapy patterns of treatments with trastuzumab (TZM), pertuzumab+trastuzumab (PTZ/TZM), lapatinib (LAP) and trastuzumab emtansine (T-DM1).
Methods:
The PRAEGNANT study is a real-time, real-world registry for patients with MBC. Patients can be registered for PRAEGNANT at any time during the course of their metastatic disease and are followed up until death. All therapy lines are documented. This analysis presents the utilization of anti-HER2 therapies as well as therapy sequences.
Results:
Of 1936 patients within PRAEGNANT at the time of database closure 451 were HER2 positive (23.3%). Within the analysis set (417 patients after an unilateral breast cancer diagnosis), of which 53% were included in PRAEGNANT in the 1stline setting, 241 were treated with TZM (58%), 237 with PTZ (57%), 85 with LAP (20%) and 125 with T-DM1 (30%) during the course of their therapies. The sequence PTZ/TZMàT-DM1 was given to 51 patients (12%). Worse ECOG, negative hormone receptor status, and visceral or brain metastases were associated with a more frequent use of this therapy sequence. Most patients received T-DM1 after a therapy with pertuzumab.
Conclusions:
Both novel therapies (PTZ/TZM and T-DM1) are utilized in a high proportion of HER2 positive breast cancer patients. As most patients receive T-DM1 after pertuzumab real world data might help to understand whether this sequence has similar efficacy like in the approval study.
Citation Format: Lux MP, Hartkopf AD, Huober J, Volz B, Taran F-A, Overkamp F, Hadji P, Tesch H, Haeberle L, Ettl J, Lueftner DI, Wallwiener M, Müller V, Beckmann MW, Belleville E, Wimberger P, Hielscher C, Geberth M, Lermann J, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Fasching PA, Janni W, Fehm TN, Wallwiener D, Brucker SY, Schneeweiss A, Kolberg H-C. Therapy landscape of patients with metastatic, HER2 positive breast cancer - Data from the real world breast cancer registry PRAEGNANT (NCT02338167) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-17-37.
Collapse
Affiliation(s)
- MP Lux
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - AD Hartkopf
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - J Huober
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - B Volz
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - F-A Taran
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - F Overkamp
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - P Hadji
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - H Tesch
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - L Haeberle
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - J Ettl
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - DI Lueftner
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - M Wallwiener
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - V Müller
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - MW Beckmann
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - E Belleville
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - P Wimberger
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - C Hielscher
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - M Geberth
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - J Lermann
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - W Abenhardt
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - C Kurbacher
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - R Wuerstlein
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - C Thomssen
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - M Untch
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - PA Fasching
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - W Janni
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - TN Fehm
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - D Wallwiener
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - SY Brucker
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - A Schneeweiss
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - H-C Kolberg
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| |
Collapse
|
5
|
Schneeweiss A, Lux MP, Hartkopf AD, Volz B, Kolberg HC, Hadji P, Tesch H, Haeberle L, Ettl J, Lüftner DI, Wallwiener M, Müller V, Beckmann MW, Belleville E, Wimberger P, Hielscher C, Geberth M, Lermann J, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Overkamp F, Huober J, Taran FA, Janni W, Wallwiener D, Brucker SY, Fasching PA, Fehm TN. Abstract P6-17-22: Progression free survival (PFS) and overall survival (OS) of patients treated with trastuzumab emtansine (T-DM1) after previous treatment with pertuzumab in patients with advanced breast cancer (NCT02338167). Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-17-22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Studies leading to the approval of trastuzumab emtansine (T-DM1) have been conducted without pertuzumab as previous therapy. Therefore data about patient characteristics and the efficacy of T-DM1 after a treatment with pertuzumab is scarce. Aim of this study was to analyze a real world patient cohort of advanced breast cancer (aBC) patients, who were treated with T-DM1 after a treatment containing pertuzumab in the metastatic setting with regard to patient characteristics and progression free survival (PFS).
Methods
The PRAEGNANT metastatic breast cancer registry (NCT02338167) is a prospective registry for metastatic breast cancer patients with focus on molecular biomarkers. Patients of all therapy lines with any kind of treatment are eligible for this registry. Collected data comprises all relevant patient and tumor characteristics, therapies, adverse events, quality of life, patient reported outcomes, response and survival (PFS/OS). Here we report on the patient characteristics and PFS data for HER2 positive patients treated with T-DM1 after a treatment with pertuzumab. Patients had to be included before or at the beginning of the T-DM1 therapy.
Results
A total of 58 patients could be identified, who were suitable for the analysis. Of those 34 were treated in the second line, 14 in the third line and 10 in the fourth line or higher. Most of the pertuzumab therapies before T-DM1 were conducted in first line (n=46; 79.3%). Median PFS for all patients was 4.8 months (95% CI: 3.0-7.8 months). Median PFS for patients treated in the 3rdline and 4thline or higher was 4.2 months(95%CI: 2.3 - NA) and 4.0 months (95%CI: 1.8-N.A.), respectively. In patients treated 2ndline with T-DM1 PFS was 7.7 months (95%CI: 2.8 – 12.2).
Conclusion
T-DM1 is effective as 2ndand further line therapy following pretreatment with pertuzumab. Overall PFS was about 5 months with 7.7 months as 2nd-line therapy. The PFS in higher therapy lines might be shorter. As the sample size of this real world cohort was rather low and analyses have to be considered exploratory, this data need to be confirmed in studies with a larger sample size.
Citation Format: Schneeweiss A, Lux MP, Hartkopf AD, Volz B, Kolberg H-C, Hadji P, Tesch H, Haeberle L, Ettl J, Lüftner DI, Wallwiener M, Müller V, Beckmann MW, Belleville E, Wimberger P, Hielscher C, Geberth M, Lermann J, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Overkamp F, Huober J, Taran F-A, Janni W, Wallwiener D, Brucker SY, Fasching PA, Fehm TN. Progression free survival (PFS) and overall survival (OS) of patients treated with trastuzumab emtansine (T-DM1) after previous treatment with pertuzumab in patients with advanced breast cancer (NCT02338167) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-17-22.
Collapse
Affiliation(s)
- A Schneeweiss
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - MP Lux
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - AD Hartkopf
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - B Volz
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - H-C Kolberg
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - P Hadji
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - H Tesch
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - L Haeberle
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - J Ettl
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - DI Lüftner
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - M Wallwiener
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - V Müller
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - MW Beckmann
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - E Belleville
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - P Wimberger
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - C Hielscher
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - M Geberth
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - J Lermann
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - W Abenhardt
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - C Kurbacher
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - R Wuerstlein
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - C Thomssen
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - M Untch
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - F Overkamp
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - J Huober
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - F-A Taran
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - W Janni
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - D Wallwiener
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - SY Brucker
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - PA Fasching
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - TN Fehm
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| |
Collapse
|
6
|
Huober J, Fasching PA, Taran FA, Volz B, Overkamp F, Kolberg HC, Hadji P, Tesch H, Haeberle L, Ettl J, Hartkopf AD, Lux MP, Lueftner D, Wallwiener M, Mueller V, Beckmann MW, Belleville E, Wimberger P, Hielscher C, Geberth M, Fersis N, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Janni W, Wallwiener D, Brucker SY, Schneeweiss A, Fehm TN. Abstract P3-11-07: Factors associated with first line chemotherapy use in patients with hormone receptor positive, HER2 negative metastatic breast cancer – data from the PRAEGNANT breast cancer registry. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p3-11-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
For breast cancer patients with metastases which are not life threatening national and international guidelines recommend the exhaustion of all antihormonal therapeutic options before recommending chemotherapy. In Germany up to now only everolimus was an additional option to overcome endocrine resistance. CDK4/6 inhibitors recently became available in Germany (Nov 2011). Aim of this analysis was the identification of predictors for a decision against an antihormonal treatment.
Methods
The PRAEGNANT metastatic breast cancer registry (NCT02338167) is a prospective registry for metastatic breast cancer patients. Besides biomarker research the description of real-world treatment data was one of the main study aims. This analysis was restricted to first line metastatic patients who were hormone receptor (HR) positive and HER2 negative. First, predictors were identified with a multiple logistic regression model. Then patients, who received chemo or not ,were compared with regard to overall survival using Cox regression analysis with the predictors for chemotherapy from above and additionally chemo status (yes/no)
Results
A total of 389 HR-positive and HER2-negative patients with detailed treatment information were included during the 1st line therapy into PRAEGNANT. Of those 173 (44.5%) received a chemotherapy, 190 an antihormone therapy (AHT) (48.8%), and 26 (6.7%) everolimus+AHT. In the multiple logistic regression model, older patients, lower graded tumors, bone only disease and previous adjuvant chemotherapy were associated with a lower rate of first line chemotherapies. BMI and number of concomitant diseases had no influence on the choice of first line metastatic therapy. In patients with visceral metastases 58.1% were treated with a 1st line chemo, while in patients with brain metastases or bone only metastases these numbers were 55.6% and 26.9%. Grading had an influence with patients having a G1, G2 and G3 tumor receiving 1st line chemo in 28.0%, 38.4% and 63.2% of the cases respectively. Patients who received chemo seemed to have a worse overall survival than patients who did not receive chemo (adjusted HR 1.58; 95% CI, 0.89 to 2.18). However, this result was not signifcant (p = 0.12). Overall survival was primarily influenced by ECOG and location of metastasis
Conclusion
The usage of chemotherapy can be predicted with age, metastasis pattern, grading and previous use of chemotherapy. However, we could not show that patients benefited from chemotherapy. On contrary, there was a tendency that patients treated with chemotherapy had poorer overall survival. Further studies with larger sample sizes are needed to confirm this claim.
Citation Format: Huober J, Fasching PA, Taran F-A, Volz B, Overkamp F, Kolberg HC, Hadji P, Tesch H, Haeberle L, Ettl J, Hartkopf AD, Lux MP, Lueftner D, Wallwiener M, Mueller V, Beckmann MW, Belleville E, Wimberger P, Hielscher C, Geberth M, Fersis N, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Janni W, Wallwiener D, Brucker SY, Schneeweiss A, Fehm TN. Factors associated with first line chemotherapy use in patients with hormone receptor positive, HER2 negative metastatic breast cancer – data from the PRAEGNANT breast cancer registry [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P3-11-07.
Collapse
Affiliation(s)
- J Huober
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - PA Fasching
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - F-A Taran
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - B Volz
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - F Overkamp
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - HC Kolberg
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - P Hadji
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - H Tesch
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - L Haeberle
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - J Ettl
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - AD Hartkopf
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - MP Lux
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - D Lueftner
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - M Wallwiener
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - V Mueller
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - MW Beckmann
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - E Belleville
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - P Wimberger
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - C Hielscher
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - M Geberth
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - N Fersis
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - W Abenhardt
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - C Kurbacher
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - R Wuerstlein
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - C Thomssen
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - M Untch
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - W Janni
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - D Wallwiener
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - SY Brucker
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - A Schneeweiss
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - TN Fehm
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| |
Collapse
|
7
|
Taran FA, Fasching PA, Volz B, Huober J, Overkamp F, Kolberg HC, Hadji P, Tesch H, Haeberle L, Ettl J, Lux MP, Hartkopf AD, Lueftner D, Wallwiener M, Müller V, Beckmann MW, Belleville E, Wimberger P, Hielscher C, Geberth M, Fersis N, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Janni W, Fehm TN, Wallwiener D, Brucker SY, Schneeweiss A. Abstract P5-21-09: Overall survival of metastatic breast cancer patients – data from the PRAEGNANT breast cancer registry. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p5-21-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Breast Cancer registries can help to understand how patient groups are treated outside clinical trials and what outcome is to expected for specific patient groups and therapy lines, which are not included into clinical trials. Here we present overall survival data according to therapy lines, patient and tumor characteristics.
Methods
The PRAEGNANT metastatic breast cancer registry (NCT02338167) is a prospective registry for breast cancer patients with focus on molecular biomarkers. Patients of all therapy lines with any kind of treatment are eligible for this registry. Collected data comprises therapies, adverse events, quality of life and other patient reported outcomes. Here we report on the comparison of overall survival data for different patient groups. For that analysis was restricted to patients included in the first therapy line for subgroup comparisons. Only for the analysis of the effect of therapy line on overall survival the complete dataset was used.
Results
A total of 1854 patients took part in this analysis. Of those 1016 were included first line, and 340, 213 and 285 patients 2nd line, 3rd lin4 and 4th line or higher respectively. A total of 339 deaths were observed. Two year survival rates (2Y-OS) for these groups were 75%, 65%, 57% and 36% (p(log-rank)<0.001). All further analyses were done only for the subset of first line treated patients with a total of 127 events. HER2 positive patients had the highest 2Y-OS rate of 84% and TNBC had the worst with 60% (see figure 1). Absolute numbers of deaths for TNBC, luminal A like, luminal B like and HER2 posives were 21, 48, 25, and 21. According to metastastic pattern the following survival rates were seen: brain (48%), other locations (69%), visceral (78%) and bone only (81%). ECOG was another factor that had a large influence on OS with ECOG 0: 83%, ECOG 1: 67% and EGOG 2+: 63% 2Y-OS. Age, BMI, number of concomitant diseases, and primary metastatic status did not have an influence on 2Y-OS.
Conclusion
This breast registry included patients over all therapy lines however mainly during the 1st line of therapy. Simple patient and tumor characteristics can classify patients into patients with differently favourable prognosis. Patients with HER2 positive disease had the best overall survival, while TNBC and luminal B like patients had the worst prognosis. As most of the patients were luminal A like 43% of all deaths occured within the group of luminal A like patients, which will need further focus for therapy development in the future.
Citation Format: Taran F-A, Fasching PA, Volz B, Huober J, Overkamp F, Kolberg HC, Hadji P, Tesch H, Haeberle L, Ettl J, Lux MP, Hartkopf AD, Lueftner D, Wallwiener M, Müller V, Beckmann MW, Belleville E, Wimberger P, Hielscher C, Geberth M, Fersis N, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Janni W, Fehm TN, Wallwiener D, Brucker SY, Schneeweiss A. Overall survival of metastatic breast cancer patients – data from the PRAEGNANT breast cancer registry [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P5-21-09.
Collapse
Affiliation(s)
- F-A Taran
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - PA Fasching
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - B Volz
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - J Huober
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - F Overkamp
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - HC Kolberg
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - P Hadji
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - H Tesch
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - L Haeberle
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - J Ettl
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - MP Lux
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - AD Hartkopf
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - D Lueftner
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - M Wallwiener
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - V Müller
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - MW Beckmann
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - E Belleville
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - P Wimberger
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - C Hielscher
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - M Geberth
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - N Fersis
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - W Abenhardt
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - C Kurbacher
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - R Wuerstlein
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - C Thomssen
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - M Untch
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - W Janni
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - TN Fehm
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - D Wallwiener
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - SY Brucker
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - A Schneeweiss
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| |
Collapse
|
8
|
Wallwiener M, Nabieva N, Haeberle L, Taran FA, Hartkopf AD, Volz B, Overkamp F, Brandl AL, Kolberg HC, Hadji P, Tesch H, Ettl J, Lux MP, Lueftner D, Belleville E, Fasching PA, Janni W, Beckmann MW, Wimberger P, Hielscher C, Fehm T, Brucker SY, Wallwiener D, Schneeweiss A, Mueller V. Abstract P6-11-10: Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p6-11-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Improved progression-free survival is considered as treatment goal for patients with metastatic breast cancer (MBC) since it is assumed to delay or prevent deterioration of quality of life.Aim of our analysis was to examine the influence of disease progression on health-related quality of life (HRQoL).
Methods: The PRAEGNANT study comprises a real-life registry for patients with MBC. HRQoL was assessed with the EORTC-QLQ-C30 Version 3.0 questionnaire at study entry and every 3 months thereafter. The primary endpoint was minimally important deterioration (MID) in global HRQoL score by ≥ five points between baseline and any follow-up assessment. A logistic regression model was built with MID (yes/no) at a follow-up timepoint as outcome variable and several covariates as predictors.
Results: In total, 329 patients were included in this analysis, with disease progression in 63 patients. Concerning the primary study aim, progression status predicted MID of global HRQoL status in addition to the other covariates. The adjusted odds ratio for the effect of progression status on MID was 2.22 (95% CI: 1.04 – 4.73). Comparisons of mean differences of QoL domains/scales yielded no differences.
Conclusions: We provide evidence that disease progression in patients with metastatic breast cancer in a real-world registry has a significant negative impact on HRQoL as measured by MID of HRQoL. This study emphasizes the relevance of avoiding progression and prolonging PFS to maintain QoL.
Citation Format: Wallwiener M, Nabieva N, Haeberle L, Taran FA, Hartkopf AD, Volz B, Overkamp F, Brandl AL, Kolberg H-C, Hadji P, Tesch H, Ettl J, Lux MP, Lueftner D, Belleville E, Fasching PA, Janni W, Beckmann MW, Wimberger P, Hielscher C, Fehm T, Brucker SY, Wallwiener D, Schneeweiss A, Mueller V. Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P6-11-10.
Collapse
Affiliation(s)
- M Wallwiener
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - N Nabieva
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - L Haeberle
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - FA Taran
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - AD Hartkopf
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - B Volz
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - F Overkamp
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - AL Brandl
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - H-C Kolberg
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - P Hadji
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - H Tesch
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - J Ettl
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - MP Lux
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - D Lueftner
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - E Belleville
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - PA Fasching
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - W Janni
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - MW Beckmann
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - P Wimberger
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - C Hielscher
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - T Fehm
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - SY Brucker
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - D Wallwiener
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - A Schneeweiss
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - V Mueller
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| |
Collapse
|
9
|
Hanker L, Hitschold T, Grafe A, Förster F, Schröder J, Janssen J, Reichert D, Hielscher C, Keitel S, Hesse T. Abstract P4-14-08: Efficacy of trastuzumab re-therapy in the clinical routine of HER2-positive breast cancer patients who relapsed after completed anti-HER2 (neo)adjuvant therapy – 5th interim analysis of the national non-interventional study (NIS) ML21589. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p4-14-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
HER2 overexpression occurs in approx. 20% of breast tumors and is associated with increased aggressiveness and mortality. Anti-HER2 re-therapy with trastuzumab (Herceptin®, T) is an established therapeutic option for the treatment of recurrent/metastatic HER2-positive breast cancer (MBC). Patients (pts) receiving T re-therapy appear to benefit from the retreatment after a relapse-free (neo)adjuvant anti-HER2 therapy.
Methods
This NIS is conducted in Germany to gain additional knowledge about efficacy of 1st-line T retreatment in the clinical routine. 122 sites enrolled a total of 239 pts with locally recurrent and/or MBC who relapsed after (neo)adjuvant treatment with T in their medical history. 230 pts met the eligibility criteria. The current analysis presents data collected between 10/2008-04/2015. Tumor progression was clinically assessed by the investigator.
Results
Median observation period for the total population (n=230) was 41.7 months (m) (range 0.4-94.5).
At start of T retreatment, 20.0% (n=46) of the pts presented with local recurrence only, 79.6% (n=183) presented with distant metastases ± local recurrence and one patient (0.4%) presented with elevated tumor markers. 27.4% (n=63) of the pts developed exclusively non-visceral metastases and 52.2% (n=120) were diagnosed with visceral (± non-visceral) metastases. Median duration of T re-therapy in the first line setting was 9.0 m (95% confidence interval (CI): 7.6-10.1). In 69.6% (n=160) of the cases, T was added to chemotherapy (CT). 15.2% of the pts (n=35) were treated with T+CT + endocrine therapy (ET).
A median progression free survival (PFS) of 10.1 m was observed among all eligible patients (n = 230) (95% CI: 8.5-12.0). The evaluation by risk groups revealed a PFS of 23.7 m (95% CI: 13.3-NE*) for patients with local recurrence only, 11.8 m (95% CI: 8.3-20.1) for patients with non-visceral metastases and 7.6 m (95% CI: 6.2-9.9) for patients with visceral metastases. *Not evaluable
Median PFS according to treatment regimen was 8.3 m for pts who were treated with T+CT (n=125, 54.3%), 17.7 m in pts who received T+CT+ET (n=35, 15.2%) and 11.2 m in pts treated with T+ET (n=38, 16.5%). Pts who received T monotherapy (n=32, 13.9%) had a median PFS of 13.4 m.
Of 230 pts, 121 deaths were documented (52.6%) within the observation period. The median overall survival (OS) was 29.6 m for all pts (95% CI: 27.3-36.8). Median OS was statistically reliable for pts with visceral metastases only: 19.4 m (95% CI: 16.9-27.3). The 2-year survival rate was 62.2% for all pts, 81.9% for pts with local recurrence only, 80.7% for pts with non-visceral metastases and 45.6% for pts with visceral metastases.
Conclusions
The survival observed for pts with HER2-positive MBC receiving T re-therapy in the clinical routine is in line with the results of recently published data. In terms of the 2-year survival rate, 81.9% of the pts with local recurrence were still alive and thus show the most favourable prognosis. T re-therapy provides an efficient treatment option regardless of given as combination-therapy together with CT and/or ET or as monotherapy.
Citation Format: Hanker L, Hitschold T, Grafe A, Förster F, Schröder J, Janssen J, Reichert D, Hielscher C, Keitel S, Hesse T. Efficacy of trastuzumab re-therapy in the clinical routine of HER2-positive breast cancer patients who relapsed after completed anti-HER2 (neo)adjuvant therapy – 5th interim analysis of the national non-interventional study (NIS) ML21589. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-14-08.
Collapse
Affiliation(s)
- L Hanker
- Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Klinik für Frauenheilkunde und Geburtshilfe, Lübeck, Germany; Klinikum Worms, Brustzentrum, Worms, Germany; MVZ Nordhausen, Nordhausen, Germany; Schwerpunktpraxis für Gynäkologische Onkologie und Palliativmedizin, Chemnitz, Germany; Onkologische Schwerpunktpraxis, Muelheim an der Ruhr, Germany; Gemeinschaftspraxis für Hämatologie und Onkologie, Westerstede, Germany; Gynäkologie Zentrum Stralsund, Stralsund, Germany; Roche Pharma AG, Grenzach-Wyhlen, Germany; Diakoniekrankenhaus, Klinik für Frauenheilkunde, Rotenburg, Germany
| | - T Hitschold
- Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Klinik für Frauenheilkunde und Geburtshilfe, Lübeck, Germany; Klinikum Worms, Brustzentrum, Worms, Germany; MVZ Nordhausen, Nordhausen, Germany; Schwerpunktpraxis für Gynäkologische Onkologie und Palliativmedizin, Chemnitz, Germany; Onkologische Schwerpunktpraxis, Muelheim an der Ruhr, Germany; Gemeinschaftspraxis für Hämatologie und Onkologie, Westerstede, Germany; Gynäkologie Zentrum Stralsund, Stralsund, Germany; Roche Pharma AG, Grenzach-Wyhlen, Germany; Diakoniekrankenhaus, Klinik für Frauenheilkunde, Rotenburg, Germany
| | - A Grafe
- Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Klinik für Frauenheilkunde und Geburtshilfe, Lübeck, Germany; Klinikum Worms, Brustzentrum, Worms, Germany; MVZ Nordhausen, Nordhausen, Germany; Schwerpunktpraxis für Gynäkologische Onkologie und Palliativmedizin, Chemnitz, Germany; Onkologische Schwerpunktpraxis, Muelheim an der Ruhr, Germany; Gemeinschaftspraxis für Hämatologie und Onkologie, Westerstede, Germany; Gynäkologie Zentrum Stralsund, Stralsund, Germany; Roche Pharma AG, Grenzach-Wyhlen, Germany; Diakoniekrankenhaus, Klinik für Frauenheilkunde, Rotenburg, Germany
| | - F Förster
- Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Klinik für Frauenheilkunde und Geburtshilfe, Lübeck, Germany; Klinikum Worms, Brustzentrum, Worms, Germany; MVZ Nordhausen, Nordhausen, Germany; Schwerpunktpraxis für Gynäkologische Onkologie und Palliativmedizin, Chemnitz, Germany; Onkologische Schwerpunktpraxis, Muelheim an der Ruhr, Germany; Gemeinschaftspraxis für Hämatologie und Onkologie, Westerstede, Germany; Gynäkologie Zentrum Stralsund, Stralsund, Germany; Roche Pharma AG, Grenzach-Wyhlen, Germany; Diakoniekrankenhaus, Klinik für Frauenheilkunde, Rotenburg, Germany
| | - J Schröder
- Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Klinik für Frauenheilkunde und Geburtshilfe, Lübeck, Germany; Klinikum Worms, Brustzentrum, Worms, Germany; MVZ Nordhausen, Nordhausen, Germany; Schwerpunktpraxis für Gynäkologische Onkologie und Palliativmedizin, Chemnitz, Germany; Onkologische Schwerpunktpraxis, Muelheim an der Ruhr, Germany; Gemeinschaftspraxis für Hämatologie und Onkologie, Westerstede, Germany; Gynäkologie Zentrum Stralsund, Stralsund, Germany; Roche Pharma AG, Grenzach-Wyhlen, Germany; Diakoniekrankenhaus, Klinik für Frauenheilkunde, Rotenburg, Germany
| | - J Janssen
- Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Klinik für Frauenheilkunde und Geburtshilfe, Lübeck, Germany; Klinikum Worms, Brustzentrum, Worms, Germany; MVZ Nordhausen, Nordhausen, Germany; Schwerpunktpraxis für Gynäkologische Onkologie und Palliativmedizin, Chemnitz, Germany; Onkologische Schwerpunktpraxis, Muelheim an der Ruhr, Germany; Gemeinschaftspraxis für Hämatologie und Onkologie, Westerstede, Germany; Gynäkologie Zentrum Stralsund, Stralsund, Germany; Roche Pharma AG, Grenzach-Wyhlen, Germany; Diakoniekrankenhaus, Klinik für Frauenheilkunde, Rotenburg, Germany
| | - D Reichert
- Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Klinik für Frauenheilkunde und Geburtshilfe, Lübeck, Germany; Klinikum Worms, Brustzentrum, Worms, Germany; MVZ Nordhausen, Nordhausen, Germany; Schwerpunktpraxis für Gynäkologische Onkologie und Palliativmedizin, Chemnitz, Germany; Onkologische Schwerpunktpraxis, Muelheim an der Ruhr, Germany; Gemeinschaftspraxis für Hämatologie und Onkologie, Westerstede, Germany; Gynäkologie Zentrum Stralsund, Stralsund, Germany; Roche Pharma AG, Grenzach-Wyhlen, Germany; Diakoniekrankenhaus, Klinik für Frauenheilkunde, Rotenburg, Germany
| | - C Hielscher
- Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Klinik für Frauenheilkunde und Geburtshilfe, Lübeck, Germany; Klinikum Worms, Brustzentrum, Worms, Germany; MVZ Nordhausen, Nordhausen, Germany; Schwerpunktpraxis für Gynäkologische Onkologie und Palliativmedizin, Chemnitz, Germany; Onkologische Schwerpunktpraxis, Muelheim an der Ruhr, Germany; Gemeinschaftspraxis für Hämatologie und Onkologie, Westerstede, Germany; Gynäkologie Zentrum Stralsund, Stralsund, Germany; Roche Pharma AG, Grenzach-Wyhlen, Germany; Diakoniekrankenhaus, Klinik für Frauenheilkunde, Rotenburg, Germany
| | - S Keitel
- Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Klinik für Frauenheilkunde und Geburtshilfe, Lübeck, Germany; Klinikum Worms, Brustzentrum, Worms, Germany; MVZ Nordhausen, Nordhausen, Germany; Schwerpunktpraxis für Gynäkologische Onkologie und Palliativmedizin, Chemnitz, Germany; Onkologische Schwerpunktpraxis, Muelheim an der Ruhr, Germany; Gemeinschaftspraxis für Hämatologie und Onkologie, Westerstede, Germany; Gynäkologie Zentrum Stralsund, Stralsund, Germany; Roche Pharma AG, Grenzach-Wyhlen, Germany; Diakoniekrankenhaus, Klinik für Frauenheilkunde, Rotenburg, Germany
| | - T Hesse
- Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Klinik für Frauenheilkunde und Geburtshilfe, Lübeck, Germany; Klinikum Worms, Brustzentrum, Worms, Germany; MVZ Nordhausen, Nordhausen, Germany; Schwerpunktpraxis für Gynäkologische Onkologie und Palliativmedizin, Chemnitz, Germany; Onkologische Schwerpunktpraxis, Muelheim an der Ruhr, Germany; Gemeinschaftspraxis für Hämatologie und Onkologie, Westerstede, Germany; Gynäkologie Zentrum Stralsund, Stralsund, Germany; Roche Pharma AG, Grenzach-Wyhlen, Germany; Diakoniekrankenhaus, Klinik für Frauenheilkunde, Rotenburg, Germany
| |
Collapse
|
10
|
Dall P, Koch T, Lenzen G, Kuhn T, Hielscher C, Reichert D, Maasberg M, Ehscheidt P, Eustermann H, Fischer G. P1-12-21: Adjuvant Trastuzumab Treatment without Adjuvant Chemotherapy in Early Breast Cancer. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p1-12-21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Trastuzumab (T) is approved in most Western countries for the treatment of early, HER2+ breast cancer (BC) parallel or sequential to adjuvant chemotherapy (CT). Nevertheless, as in metastatic disease, the antibody seems to be used without chemotherapy in a selected group of HER2+ patients (pt). The purpose of this analysis is to characterize this subgroup as well as describe safety and efficacy outcome parameters in this German prospective observation trial.
Methods: At present, 2870 patients (pts) have been enrolled and documented in this ongoing non-interventional study from 270 German centers. At data base closure for this analysis, sufficient documentation was available from 2422 eligible pts.
Results: The proportion of pts receiving T without preceding or concomitant CT (noCT) was 180/2422 (7.4%). This subgroup was characterized by higher age (median 58 vs.56 in the CT group, p=0.0026; ≥70 years: 18%/10%), smaller primaries (pT1 49%/43%, p=0.11), more favorable grading (G3 45%/53%, p=0.045), a higher proportion of positive hormone receptor (67%/61%, p=0.096) and less radiotherapy (64%/79%, p<0.0001). The strong association to radiotherapy is probably due to the fact, that the choice of this additional modality reflects the overall risk assessment of the pt.
In contrast, there was no difference in nodal involvement (pN0: 52%/51%; positive nodes: mean 2.5/2.4). In multivariate analysis (logistic regression model, not incorporating radiotherapy), hormone receptor status is not predictive (p=0.41), while age ≥65 (p=0.0011), grade 1/2 (p=0.046) and pT1 (p=0.089) independently remain at least borderline significant. The mean number of T administrations was 18 and the median duration of T therapy was 12 months in the noCT group as well as the CT group. 57% of the noCT pts received adjuvant endocrine therapy. In the CT group, 81% received anthracyclines and 61% taxanes.
Based on a still low number of only 13 observed events in the noCT group, no differences in relapse-free survival could be detected (p=0.38). Pathological cardiac findings in the pt's history was not predictive of therapy selection (6%/7%) and were also similarly distributed at the end of T therapy (7%/8%). Cardiac function disorders of CTC grade 3/4 were reported in 1% of both groups, across all grades slightly less frequent in the noCT group (2.8%/4.0%).
Conclusions: A small, but distinct group of early BC pts without adjuvant chemotherapy receives T treatment for HER2+ disease. These patients are characterized by higher age and favorable primary tumor staging and grading, but not by cardiac comorbidities.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P1-12-21.
Collapse
Affiliation(s)
- P Dall
- 1Städt. Klinikum, Lüneburg, Germany; Klinikum Nürnberg-Nord, Nürnberg, Germany; Praxis, Osnabrück, Germany; Brustzentrum, Stuttgart, Germany; Praxis, Stralsund, Germany; Praxis, Westerstede, Germany; Praxis, Mayen, Germany; Praxis, Neuwied, Germany; WiSP, Langenfeld, Germany; Landkreis Mittweida Khs., Mittweida, Germany
| | - T Koch
- 1Städt. Klinikum, Lüneburg, Germany; Klinikum Nürnberg-Nord, Nürnberg, Germany; Praxis, Osnabrück, Germany; Brustzentrum, Stuttgart, Germany; Praxis, Stralsund, Germany; Praxis, Westerstede, Germany; Praxis, Mayen, Germany; Praxis, Neuwied, Germany; WiSP, Langenfeld, Germany; Landkreis Mittweida Khs., Mittweida, Germany
| | - G Lenzen
- 1Städt. Klinikum, Lüneburg, Germany; Klinikum Nürnberg-Nord, Nürnberg, Germany; Praxis, Osnabrück, Germany; Brustzentrum, Stuttgart, Germany; Praxis, Stralsund, Germany; Praxis, Westerstede, Germany; Praxis, Mayen, Germany; Praxis, Neuwied, Germany; WiSP, Langenfeld, Germany; Landkreis Mittweida Khs., Mittweida, Germany
| | - T Kuhn
- 1Städt. Klinikum, Lüneburg, Germany; Klinikum Nürnberg-Nord, Nürnberg, Germany; Praxis, Osnabrück, Germany; Brustzentrum, Stuttgart, Germany; Praxis, Stralsund, Germany; Praxis, Westerstede, Germany; Praxis, Mayen, Germany; Praxis, Neuwied, Germany; WiSP, Langenfeld, Germany; Landkreis Mittweida Khs., Mittweida, Germany
| | - C Hielscher
- 1Städt. Klinikum, Lüneburg, Germany; Klinikum Nürnberg-Nord, Nürnberg, Germany; Praxis, Osnabrück, Germany; Brustzentrum, Stuttgart, Germany; Praxis, Stralsund, Germany; Praxis, Westerstede, Germany; Praxis, Mayen, Germany; Praxis, Neuwied, Germany; WiSP, Langenfeld, Germany; Landkreis Mittweida Khs., Mittweida, Germany
| | - D Reichert
- 1Städt. Klinikum, Lüneburg, Germany; Klinikum Nürnberg-Nord, Nürnberg, Germany; Praxis, Osnabrück, Germany; Brustzentrum, Stuttgart, Germany; Praxis, Stralsund, Germany; Praxis, Westerstede, Germany; Praxis, Mayen, Germany; Praxis, Neuwied, Germany; WiSP, Langenfeld, Germany; Landkreis Mittweida Khs., Mittweida, Germany
| | - M Maasberg
- 1Städt. Klinikum, Lüneburg, Germany; Klinikum Nürnberg-Nord, Nürnberg, Germany; Praxis, Osnabrück, Germany; Brustzentrum, Stuttgart, Germany; Praxis, Stralsund, Germany; Praxis, Westerstede, Germany; Praxis, Mayen, Germany; Praxis, Neuwied, Germany; WiSP, Langenfeld, Germany; Landkreis Mittweida Khs., Mittweida, Germany
| | - P Ehscheidt
- 1Städt. Klinikum, Lüneburg, Germany; Klinikum Nürnberg-Nord, Nürnberg, Germany; Praxis, Osnabrück, Germany; Brustzentrum, Stuttgart, Germany; Praxis, Stralsund, Germany; Praxis, Westerstede, Germany; Praxis, Mayen, Germany; Praxis, Neuwied, Germany; WiSP, Langenfeld, Germany; Landkreis Mittweida Khs., Mittweida, Germany
| | - H Eustermann
- 1Städt. Klinikum, Lüneburg, Germany; Klinikum Nürnberg-Nord, Nürnberg, Germany; Praxis, Osnabrück, Germany; Brustzentrum, Stuttgart, Germany; Praxis, Stralsund, Germany; Praxis, Westerstede, Germany; Praxis, Mayen, Germany; Praxis, Neuwied, Germany; WiSP, Langenfeld, Germany; Landkreis Mittweida Khs., Mittweida, Germany
| | - G Fischer
- 1Städt. Klinikum, Lüneburg, Germany; Klinikum Nürnberg-Nord, Nürnberg, Germany; Praxis, Osnabrück, Germany; Brustzentrum, Stuttgart, Germany; Praxis, Stralsund, Germany; Praxis, Westerstede, Germany; Praxis, Mayen, Germany; Praxis, Neuwied, Germany; WiSP, Langenfeld, Germany; Landkreis Mittweida Khs., Mittweida, Germany
| |
Collapse
|
11
|
Budner M, Heinrich J, Ruhland F, Hielscher C. [Ductal carcinoma of the male breast]. Zentralbl Gynakol 1999; 120:551-4. [PMID: 9880894] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Abstract
Ductal carcinoma in the breast of a 64-year-old male is reported. Diagnosis, therapy, prognosis and follow-up are discussed. Current standard therapy is ablatio mammae, with axillary lymph node dissection. A decision in respect of chemotherapy depends on the results of staging. A follow-up control of the patients for early detection and therapy of metastasis is recommended. Our data as well as recent data from literature suggest that with respect to TNM Stages in mammary carcinoma, there is no prognostic difference between men and women.
Collapse
Affiliation(s)
- M Budner
- Klinik für Gynäkologie und Geburtshilfe Stralsund
| | | | | | | |
Collapse
|